Lupin Atlantis Holdings SA and Lupin Inc. v. Xian-Ming Zeng, et al.

CourtDistrict Court, S.D. Florida
DecidedOctober 21, 2025
Docket0:23-cv-61621
StatusUnknown

This text of Lupin Atlantis Holdings SA and Lupin Inc. v. Xian-Ming Zeng, et al. (Lupin Atlantis Holdings SA and Lupin Inc. v. Xian-Ming Zeng, et al.) is published on Counsel Stack Legal Research, covering District Court, S.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Lupin Atlantis Holdings SA and Lupin Inc. v. Xian-Ming Zeng, et al., (S.D. Fla. 2025).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF FLORIDA

CASE NO. 23-61621-CIV-DAMIAN/Reid

LUPIN ATLANTIS HOLDINGS SA and LUPIN INC.,

Plaintiffs, v.

XIAN-MING ZENG, et al.,

Defendants. ________________________________________/

ORDER GRANTING DEFENDANTS AXEL PERLWITZ AND WILLIAM SCHACHTNER’S MOTION FOR SUMMARY JUDGMENT ON COUNT VI (BREACH OF FIDUCIARY DUTY) [ECF NO. 201]

THIS CAUSE is before the Court on Defendants Axel Perlwitz and William Schachtner’s Motion for Summary Judgment on Count VI (Breach of Fiduciary Duty) [ECF No. 201 (“Motion”)], filed March 11, 2025. THE COURT has reviewed the Motion, the unredacted Response and Reply [ECF Nos. 240-2 and 289-6], and the pertinent portions of the record and is otherwise fully advised. The Court also heard argument from the parties, who appeared through counsel, before the undersigned on May 28, 2025. For the reasons set forth on the record, and as further detailed below, the Motion is granted. I. RELEVANT FACTUAL BACKGROUND1 This case stems from a dispute between an employer and its former employees. Plaintiffs, Lupin Atlantis Holdings SA and Lupin Inc. (collectively, “Lupin”), operate a

1 The parties did not file a Joint Statement of Undisputed Facts as required by this Court’s Scheduling Order, entered on April 5, 2024. See ECF No. 62. The facts relevant to the instant multinational pharmaceutical company that engages in the research and development of branded and generic pharmaceutical products sold globally. SMF ¶ 1; see also First Amended Complaint [ECF No. 31 (“Amended Complaint”)] ¶¶ 2, 24. Defendant Transpire Bio, Inc. (“Transpire”) is a pharmaceutical company that

develops generic inhalation drug delivery medicines. SMF ¶ 2. Transpire is an indirect subsidiary of non-party Smoore International Holdings Limited (“Smoore”), a global leader in electronic cigarette and vaping manufacturing. Resp. at 2; Am. Compl. ¶ 4. Transpire has several generic and branded products in development, but as of the filing of this lawsuit, had not yet obtained FDA approval for, marketed, or launched any products. SMF ¶¶ 60–66. Transpire was incorporated in Florida on April 30, 2022, as a wholly owned subsidiary of Smoore. Id. ¶ 36. Defendant Dr. Xian-Ming Zeng (“Zeng”) is the chief executive officer (“CEO”) of Transpire. Id. ¶ 3. Defendants Dr. Axel Perlwitz (“Perlwitz”) and William Schachtner

(“Schachtner”) are current Transpire executives. Id. All three of these individual Defendants are former employees of Lupin who did not have non-compete agreements with Lupin. Id. ¶¶ 3, 59. Lupin hired Zeng in 2013 to launch Lupin’s Center of Excellence for Inhalation Research. Id. ¶ 18. Schachtner was Lupin’s Senior Director of Project and Manufacturing Management, and Perlwitz was Lupin’s Senior Director of Regulatory Affairs. Id. ¶¶ 41, 44.

Motion now before the Court are taken from the following submissions: (1) Defendants’ Rule 56.1 Statement of Material Facts (herein, “SMF”), filed under seal [ECF No. 213-1]; (2) Plaintiffs’ Opposition to Defendants’ SMF, filed under seal [ECF No. 240-1]; and (3) Defendant’s Reply SMF, filed under seal [ECF No. 289-10]. While the parties dispute the relevance and materiality of some of the facts contained therein, they agree that they are undisputed, unless otherwise noted. The Court views the facts in the light most favorable to the non-moving party, Plaintiffs, in considering the summary judgment materials. Chavez v. Mercantil Commercebank, N.A., 701 F.3d 896, 899 (11th Cir. 2012). While employed at Lupin, Zeng oversaw the drug development and FDA approval activities for Lupin’s Coral Springs, Florida, inhalation portfolio. Id. ¶ 26. On April 20, 2021, a representative of Smoore contacted Zeng via email regarding a potential collaboration to optimize vaping technology and inhalation medicines. Id. ¶ 30. Six

months later, Zeng ultimately resigned from Lupin on October 1, 2021, and began working with Smoore. Id. ¶ 35. One issue in this case stems from the fact that Zeng’s employment agreement with Lupin contained a one-year non-solicitation covenant. Id. ¶ 20. Dr. Mark Lepore (“Lepore”), Transpire’s Chief Medical Officer, was employed by Lupin until approximately December 2020. Id. ¶ 40. While at Lupin, Lepore was a colleague of Zeng, Perlwitz, and Schachtner. Id. In March 2022, Perlwitz and Schachtner each reached out to Lepore to inquire about potential career opportunities. Id. ¶¶ 41, 43. Perlwitz emailed Lepore on March 22, 2022, explaining, “I have made the decision that it is time to move on to a new endeavor . . . If you become aware of any leads you may think could be interesting,

please do let me know.” Id. ¶ 43, Ex. 15. Similarly, Schachtner emailed Lepore on March 25, 2022, seeking “other career options to better suit my skills” and asking if Lepore knew of “some company that might have opportunities.” Id. ¶ 41, Ex. 11. Shortly thereafter, in May 2022, Spectrum Dynamic Research Corp. (“Spectrum”),2 an affiliate of Smoore, offered Schachtner and Perlwitz employment. SMF ¶¶ 41–44. In July 2022, Schachtner began working at Spectrum as Chief Technical Operations Officer. Id. ¶ 42. In May 2022, Perlwitz informed Lupin that he intended to resign on July 1, 2022, but he deferred his resignation and started his employment with Spectrum on October 6, 2022, pursuant to an agreement with Lupin. Id. ¶¶ 44, 46–47.

2 Spectrum was later discontinued and its employees moved to Transpire. SMF ¶ 39. On August 22, 2023, Lupin filed the present action against Zeng, Transpire, Perlwitz, and Schachtner asserting claims for misappropriation of trade secrets under federal and state law against Zeng and Transpire (Counts I and II), conversion against Zeng (Count III), breach of contract against Zeng (Count IV), breach of fiduciary duty against Zeng (Count V), civil

conspiracy against all the Defendants (Count VI), and breach of fiduciary duty against Perlwitz and Schachtner (Count VII). [ECF No. 1]. On January 12, 2024, Lupin filed a First Amended Complaint, the operative pleading, asserting eight causes of action: misappropriation of trade secrets under federal and state law against Zeng and Transpire (Counts I and II), breach of contract against Zeng (Count III), breach of fiduciary duty against Zeng (Count IV), civil conspiracy against all the Defendants (Count V), breach of fiduciary duty against Perlwitz and Schachtner (Count VI), aiding and abetting breach of contract against Perlwitz and Schachtner (Count VII), and tortious interference with contractual relationship against Transpire, Perlwitz, and Schachtner (Count VII). [ECF No. 31 (“Amended Complaint”)].3

In the Motion now before the Court, Defendants Perlwitz and Schachtner seek summary judgment as to the breach of fiduciary duty claim asserted against them in Count VI of the Amended Complaint. The Motion is fully briefed and ripe for adjudication. The undersigned also heard argument from the parties, who appeared through counsel before the undersigned on May 28, 2025. See ECF No. 296.

3 On October 15, 2024, this Court dismissed Count V (civil conspiracy), Count VII (aiding and abetting), and Count VIII (tortious interference) of the Amended Complaint. See ECF No. 121. II. LEGAL STANDARD “A party may move for summary judgment, identifying each claim or defense—or the part of each claim or defense—on which summary judgment is sought.” Fed. R. Civ. P. 56(a). “The court shall grant summary judgment if the movant shows that there is no genuine

dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Janice Burgos v. Michael Chertoff
274 F. App'x 839 (Eleventh Circuit, 2008)
David W. Ellis, Jr. v. Gordon R. England
432 F.3d 1321 (Eleventh Circuit, 2005)
Laura Skop v. City of Atlanta, Georgia
485 F.3d 1130 (Eleventh Circuit, 2007)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Roger Chavez v. Mercantil Commercebank, N.A.
701 F.3d 896 (Eleventh Circuit, 2012)
Janet Feliciano v. City of Miami Beach
707 F.3d 1244 (Eleventh Circuit, 2013)
Furmanite America, Inc. v. T.D. Williamson, Inc.
506 F. Supp. 2d 1134 (M.D. Florida, 2007)
Fish v. Adams
401 So. 2d 843 (District Court of Appeal of Florida, 1981)
National Railroad Passenger v. Veolia Transportation Services, Inc.
791 F. Supp. 2d 33 (District of Columbia, 2011)
Treco International S.A. v. Kromka
706 F. Supp. 2d 1283 (S.D. Florida, 2010)
Connelly v. Special Road & Bridge District No. 5
126 So. 794 (Supreme Court of Florida, 1930)
Terry Roberts Site Work, Inc. v. Unemployment Appeals Commission
908 So. 2d 592 (District Court of Appeal of Florida, 2005)
Hennegan Co. v. Arriola
855 F. Supp. 2d 1354 (S.D. Florida, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Lupin Atlantis Holdings SA and Lupin Inc. v. Xian-Ming Zeng, et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/lupin-atlantis-holdings-sa-and-lupin-inc-v-xian-ming-zeng-et-al-flsd-2025.